For:

• Treatment of HBeAgpositive or HBeAg-negative-chronic hepatitis B in adult patients with
  compensated liver disease and evidence of viral replication, increased ALT and histologically verified liver inflammation and/or fibrosis.
• Treatment of chronic hepatitis C in adult patients who are positive for serum HCV-RNA, including patients with compensated cirrhosis and/or co-infected with clinically stable HIV. The optimal way to use it in patients with chronic hepatitis C is in combination with ribavirin. The combination with ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon Alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin. Monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.